AIM ImmunoTech Inc.

NYSE:AIM

Biological Products, (No Diagnostic Substances)·OCALA, FL

CEO

Equels Thomas K

Summary Financials

Revenue

$202,000

+43.3% YoY

FY 2024

Adj. EBITDA

-$31.9M

-15780.7% margin

FY 2024

Net Income

-$29.0M

-14337.6% margin

FY 2024

EPS (Diluted)

-$0.60

FY 2024

Stock Price

$0.70

-3.4%

2026-03-10

52W Range

$0.61 – $3.28

P/E Ratio

-1.2x

Market Cap

$2.0M

Cash

$5.4M

FY 2024

Total Debt

$4.2M

FY 2021

Net Cash

$1.3M

FY 2021

Enterprise Value

$741,179.8

Debt / EBITDA

0.0x

FY 2024

EV / EBITDA

-0.0x

Employees

—

Revenue

$202,000

+43.3% YoY

FY 2024

Adj. EBITDA

-$31.9M

-15780.7% margin

FY 2024

Net Income

-$29.0M

-14337.6% margin

FY 2024

EPS (Diluted)

-$0.60

FY 2024

Stock Price

$0.70

-3.4%

2026-03-10

52W Range

$0.61 – $3.28

P/E Ratio

-1.2x

Market Cap

$2.0M

Cash

$5.4M

FY 2024

Total Debt

$4.2M

FY 2021

Net Cash

$1.3M

FY 2021

Enterprise Value

$741,179.8

Debt / EBITDA

0.0x

FY 2024

EV / EBITDA

-0.0x

Employees

—